We have a mechanistically and structurally diverse portfolio of small molecules which have the potential to be first in class with multiple applicability across some of the most common types of cancer.
|Programme||Discovery||Lead Optimisation||Preclinical Development|
|PMX 500 - Telomere targeting agents (broad spectrum activity)|
|PMX 700 - repair resistant DNA-interactive agents (broad spectrum activity)|
|PMX 900 - Base Excision Repair inhibitors, undisclosed target (broad spectrum activity)|